Sometimes, a primary TB infection of the skin will heal only for lupus vulgaris or TB verrucosa cutis to develop in the same location. Some types, such as lupus vulgaris, may also increase the ...

At around the start of the 20th century, scientist Niels Ryberg Finsen developed a light-based treatment for lupus vulgaris, a form of TB that affects the face. Finsen’s work won him a Nobel ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses two ongoing trials for autoimmunity indications in the US and how AlloNK differs from traditional B-cell depletion strategies.

Jones Financial Companies Lllp increased its holdings in argenx SE (NASDAQ:ARGX – Free Report) by 1,016.7% during the fourth ...

Artiva Biotherapeutics' CEO Fred Aslan, MD, discusses the concept of an immune reset and what the company is tracking in ...

(NASDAQ:ARGX – Get Free Report) was upgraded by investment analysts at Sanford C. Bernstein from a “market perform” rating to ...

Artiva Biotherapeutics, Inc.’s ARTV share price has surged by 15.10%, which has investors questioning if this is right time to sell.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

The new data show "robust benefit in lupus and DM,” William Blair analysts ... multiple sclerosis and pemphigus vulgaris (PV) across 50 sites in the U.S. and Europe. The biotech plans to share ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Rarely, minocycline can cause hypersensitivity, drug-induced lupus erythematosus ... is approved for the treatment of acne vulgaris (and rosacea). Both nicotinamide and zinc oxide have anti ...

Acne lesions are usually indistinguishable from acne vulgaris, both in appearance and ... findings that are also observed in systemic lupus erythematosus (SLE), a prototype autoimmune disease.